Endovia Health Sciences, Inc. (EDVA) shareholders
EDVANYSEBeveragesFiscal year ends December 31
$0.18+0.02 (+13.45%)
Close on Nov 13, 2026Market cap $137.15KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
4.3%
0M of 6M shares
Institutional holders
18
6 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Devereux William T | 1,005,000 | 29.40% | 13D (active) | Jul 31, 2025 |
| Yorke Justin W | 907,979 | 28.60% | 13D (active) | Jul 31, 2025 |
| C/M Capital Partners, LP Joint filing with C/M Capital Master Fund, LP (7.20%), Thomas Walsh (7.20%) and 1 more | 797,592 | 7.20% | 13G (passive) | Oct 15, 2026 |
| Caple Frederick William | 767,500 | 24.10% | 13D (active) | Jul 31, 2025 |
| Meissner William R. | 752,500 | 23.80% | 13D (active) | Jul 31, 2025 |
| Fore Thomas Butler | 750,000 | 23.70% | 13D (active) | Jul 31, 2025 |
| Tong Magdalene | 200,000 | 7.70% | 13G (passive) | Jul 31, 2025 |
| Nistico Robert | 180,470 | 7.10% | 13D (active) | Jul 31, 2025 |
| Aida Aragon | 150,000 | 5.80% | 13G (passive) | Jul 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EDVA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 87,105 | 1.36% | $54.00K | New | 0.00% |
| Phraction Management LLC | 30,912 | 0.48% | $19.17K | +13,412 | 0.00% |
| Summit Trail Advisors, LLC | 25,000 | 0.39% | $15.50K | – | 0.00% |
| Geode Capital Management, LLC | 17,148 | 0.27% | $10.63K | +2,788 | 0.00% |
| Truist Financial Corp | 16,955 | 0.26% | $10.51K | +8,750 | 0.00% |
| Lifetime Wealth Management P.C. | 16,513 | 0.26% | $10.24K | – | 0.01% |
| Compass Financial Management LLC | 16,125 | 0.25% | $10.00K | New | 0.00% |
| Virtu Financial LLC | 14,974 | 0.23% | $9.00K | −10,072 | 0.00% |
| Point72 Asset Management, L.P. | 14,238 | 0.22% | $8.83K | New | 0.00% |
| Hrt Financial LP | 14,172 | 0.22% | $8.00K | −19,442 | 0.00% |
| Choreo, LLC | 8,507 | 0.13% | $5.27K | – | 0.00% |
| StoneX Group Inc. | 7,038 | 0.11% | $5.35K | New | 0.00% |
| Goldman Sachs Group Inc | 5,101 | 0.08% | $3.16K | New | 0.00% |
| Vanguard Capital Management LLC | 2,734 | 0.04% | $1.70K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 1,005 | 0.02% | $623 | – | 0.00% |
| Harbour Investments, Inc. | 118 | 0.00% | $73 | New | 0.00% |
| Delos Wealth Advisors, LLC | 4 | 0.00% | $3 | – | 0.00% |
| SBI Securities Co., Ltd. | 1 | 0.00% | $1 | −17 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 0M | 4.3% | 6 / 3 | 3 / 4 | 0M | 0M |
| Q1 2026 | 16 | 0M | 2.7% | 6 / 3 | 2 / 3 | 0M | 0M |
| Q4 2025 | 14 | 0M | 0.8% | 3 / 4 | 2 / 6 | 0M | 0M |
| Q3 2025 | 17 | 0M | 0.4% | 6 / 1 | 2 / 1 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.3% | 4 / 2 | 2 / 3 | 0M | 0M |
| Q1 2025 | 11 | 0M | 0.3% | 11 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brady James Cobb | Interim CEO, Director | – | – | Jun 10, 2026 |
| Robert Nistico | CEO and Chairman, Director, 10% owner | 38,053 | 0.59% | Oct 15, 2025 |
| Michael Breen Bondurant | Chief Operating Officer | – | – | Jun 18, 2026 |
| Martin P. Scott | Interim CFO | – | – | Jun 10, 2026 |
| William T. Devereux | Chief Financial Officer | – | – | Oct 15, 2025 |
| William R. Meissner | President and CMO, 10% owner | – | – | Oct 14, 2025 |
| Frederick William Caple | Director | 1,875 | 0.03% | Jun 10, 2026 |
| Thomas Butler Fore | Director | – | – | Jun 10, 2026 |
| Knuettel Francis II | Director | 30,000 | 0.47% | Jun 10, 2026 |
| Justin W. Yorke | Director | 19,151,440 | 298.66% | Oct 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frederick William Caple Director | Apr 19, 2024 | Award | +1,875 | – | – | 1,875 |
| Robert Nistico CEO and Chairman, Director | Mar 5, 2024 | Award | +4,000 | – | – | 38,053 |
| Robert Nistico CEO and Chairman, Director | Jun 16, 2023 | Buy | +7,000 | $1.01 | $7.07K | 1,386,000 |
| Robert Nistico CEO and Chairman, Director | Apr 14, 2023 | Buy | +12,000 | $1.15 | $13.80K | 1,379,000 |
| Robert Nistico CEO and Chairman, Director | Apr 13, 2023 | Buy | +7,000 | $1.17 | $8.19K | 1,357,000 |
| Robert Nistico CEO and Chairman, Director | Apr 13, 2023 | Buy | +10,000 | $1.17 | $11.70K | 1,367,000 |
| Robert Nistico CEO and Chairman, Director | Jun 16, 2022 | Buy | +1,000 | $1.69 | $1.69K | 1,327,070 |
| Robert Nistico CEO and Chairman, Director | Jun 16, 2022 | Buy | +1,000 | $1.67 | $1.67K | 1,326,070 |
| Robert Nistico CEO and Chairman, Director | Jun 16, 2022 | Buy | +1,000 | $1.69 | $1.69K | 1,325,070 |
| Robert Nistico CEO and Chairman, Director | Jun 15, 2022 | Buy | +315 | $1.82 | $573 | 1,323,385 |
| Robert Nistico CEO and Chairman, Director | Jun 15, 2022 | Buy | +685 | $1.83 | $1.25K | 1,324,070 |
| Robert Nistico CEO and Chairman, Director | Jun 3, 2022 | Buy | +1,000 | $2.07 | $2.07K | 1,323,070 |
| Robert Nistico CEO and Chairman, Director | Jun 3, 2022 | Buy | +1,000 | $2.04 | $2.04K | 1,322,070 |
| Robert Nistico CEO and Chairman, Director | May 27, 2022 | Buy | +2,000 | $2.12 | $4.24K | 1,319,070 |
| Robert Nistico CEO and Chairman, Director | May 27, 2022 | Buy | +1,000 | $2.03 | $2.03K | 1,320,070 |
| Robert Nistico CEO and Chairman, Director | May 27, 2022 | Buy | +1,000 | $2.04 | $2.04K | 1,321,070 |
| Robert Nistico CEO and Chairman, Director | May 26, 2022 | Buy | +2,000 | $1.95 | $3.90K | 1,317,070 |
| Robert Nistico CEO and Chairman, Director | May 26, 2022 | Buy | +2,000 | $1.95 | $3.90K | 1,315,070 |
| Robert Nistico CEO and Chairman, Director | May 26, 2022 | Buy | +2,000 | $1.99 | $3.98K | 1,313,070 |
| Robert Nistico CEO and Chairman, Director | May 26, 2022 | Buy | +1,000 | $1.94 | $1.94K | 1,311,070 |
| Dean Scott Huge Chief Financial Officer | Oct 16, 2020 | Award | +140,000 | $0.75 | $105.00K | 727,315 |
| Michael J. West Director | Jun 21, 2019 | Sale | −8,000,000 | $0.03 | $240.00K | 344,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
42.84%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
+51.3%
From 0M shares
Short volume, 20 days
40.5%
Of volume reported to FINRA
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Endovia Health Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,129,792 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?